GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Shiller PE Ratio

HAE (Haemonetics) Shiller PE Ratio : 51.32 (As of Apr. 11, 2025)


View and export this data going back to 1991. Start your Free Trial

What is Haemonetics Shiller PE Ratio?

As of today (2025-04-11), Haemonetics's current share price is $60.04. Haemonetics's E10 for the quarter that ended in Dec. 2024 was $1.17. Haemonetics's Shiller PE Ratio for today is 51.32.

The historical rank and industry rank for Haemonetics's Shiller PE Ratio or its related term are showing as below:

HAE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 29.07   Med: 93.01   Max: 223.42
Current: 51.32

During the past years, Haemonetics's highest Shiller PE Ratio was 223.42. The lowest was 29.07. And the median was 93.01.

HAE's Shiller PE Ratio is ranked worse than
80.57% of 283 companies
in the Medical Devices & Instruments industry
Industry Median: 25.54 vs HAE: 51.32

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Haemonetics's adjusted earnings per share data for the three months ended in Dec. 2024 was $0.740. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.17 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Haemonetics Shiller PE Ratio Historical Data

The historical data trend for Haemonetics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Shiller PE Ratio Chart

Haemonetics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 143.02 161.98 95.09 100.20 85.52

Haemonetics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.57 85.52 76.10 70.61 66.63

Competitive Comparison of Haemonetics's Shiller PE Ratio

For the Medical Devices subindustry, Haemonetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's Shiller PE Ratio falls into.


;
;

Haemonetics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Haemonetics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=60.04/1.17
=51.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Haemonetics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.74/133.1571*133.1571
=0.740

Current CPI (Dec. 2024) = 133.1571.

Haemonetics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.060 99.621 -0.080
201506 -0.010 100.684 -0.013
201509 0.250 100.392 0.332
201512 -1.170 99.792 -1.561
201603 -0.173 100.470 -0.229
201606 -0.200 101.688 -0.262
201609 0.380 101.861 0.497
201612 0.300 101.863 0.392
201703 -0.984 102.862 -1.274
201706 0.380 103.349 0.490
201709 0.380 104.136 0.486
201712 -0.120 104.011 -0.154
201803 0.220 105.290 0.278
201806 -0.050 106.317 -0.063
201809 0.350 106.507 0.438
201812 0.350 105.998 0.440
201903 0.400 107.251 0.497
201906 -0.170 108.070 -0.209
201909 0.720 108.329 0.885
201912 0.580 108.420 0.712
202003 0.350 108.902 0.428
202006 0.210 108.767 0.257
202009 0.940 109.815 1.140
202012 0.620 109.897 0.751
202103 -0.220 111.754 -0.262
202106 -0.090 114.631 -0.105
202109 0.290 115.734 0.334
202112 0.450 117.630 0.509
202203 0.190 121.301 0.209
202206 0.380 125.017 0.405
202209 0.640 125.227 0.681
202212 0.640 125.222 0.681
202303 0.570 127.348 0.596
202306 0.800 128.729 0.828
202309 0.480 129.860 0.492
202312 0.610 129.419 0.628
202403 0.400 131.776 0.404
202406 0.740 132.554 0.743
202409 0.660 133.029 0.661
202412 0.740 133.157 0.740

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Haemonetics  (NYSE:HAE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Haemonetics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Haemonetics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277